A5016119733- CAR-T cell therapy research
- Synthesis and Biological Evaluation
- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- HIV Research and Treatment
- Chronic Lymphocytic Leukemia Research
- Hippo pathway signaling and YAP/TAZ
- Cell death mechanisms and regulation
- Quinazolinone synthesis and applications
- Calcium signaling and nucleotide metabolism
- Ubiquitin and proteasome pathways
University of North Carolina at Chapel Hill
2024-2025
University of Colorado Anschutz Medical Campus
2023-2024
Monoclonal antibodies targeting CD38 are important for treatment of both newly diagnosed and relapsed multiple myeloma (MM). Daratumumab isatuximab anti-CD38 with the US Food Drugs Administration approval in different combinations. Despite good initial efficacy, patients inevitably develop drug resistance. Whether can be effectively re-treated these subsequent lines therapy is unclear. Thus far, studies have mostly been limited to clinical retrospectives short washout periods. To answer...
Abstract HIV cure strategies that aim to induce viral reactivation for immune clearance leverage latency reversal agents modulate host pathways which directly or indirectly facilitate reactivation. Inhibition of BET (bromo and extra-terminal domain) family member BRD4 reverses latency, but enthusiasm the use inhibitors in studies is tempered by concerns over inhibition other members dose-limiting toxicities oncology trials. Here we evaluated potential bivalent chemical degraders targeted as...
Abstract T cell–engaging antibodies (TCEs) are showing promising efficacy in relapsed/refractory multiple myeloma, even patients that relapsed after B-cell maturation antigen (BCMA)-targeted therapy. Patients with myeloma may have compromised T-cell health unaccounted for by preclinical models. Here, we use Myeloma Drug Sensitivity Testing (My-DST) ex vivo measurement of anti-multiple cytotoxicity the trispecific CD38/CD28xCD3 TCE SAR442257 through activation patients’ own endogenous cells...
ABSTRACT HIV cure strategies that aim to induce viral reactivation for immune clearance leverage latency reversal agents modulate host pathways which directly or indirectly facilitate reactivation. Inhibition of bromo and extra-terminal domain (BET) family member BRD4 reverses latency, but enthusiasm the use BET inhibitors in studies is tempered by concerns over inhibition other members dose-limiting toxicities oncology trials. Here, we evaluated potential bivalent chemical degraders...
<p>Ratio of CD8+ to CD4+ T cells does not appear affect sensitivity SAR442257</p>
<p>The percentage of MM cells CD28+ does not appear to affect sensitivity SAR442257</p>
<p>Sensitivity to SAR4422557 across treatment groups</p>
<p>Ratio of CD8+ to CD4+ T cells does not appear affect sensitivity SAR442257</p>
<p>The percentage of MM cells CD28+ does not appear to affect sensitivity SAR442257</p>
<p>CD38 expression across treatment groups</p>
<div>Abstract<p>T cell–engaging antibodies (TCEs) are showing promising efficacy in relapsed/refractory multiple myeloma, even patients that relapsed after B-cell maturation antigen (BCMA)-targeted therapy. Patients with myeloma may have compromised T-cell health unaccounted for by preclinical models. Here, we use Myeloma Drug Sensitivity Testing (My-DST) <i>ex vivo</i> measurement of anti-multiple cytotoxicity the trispecific CD38/CD28xCD3 TCE SAR442257 through...
<p>Multi-epitope CD38-FITC binds CD38 in cells treated with SAR442257.</p>
<p>CD38 expression across treatment groups</p>
<p>Sensitivity to SAR4422557 across treatment groups</p>
<p>Multi-epitope CD38-FITC binds CD38 in cells treated with SAR442257.</p>
<div>Abstract<p>T cell–engaging antibodies (TCEs) are showing promising efficacy in relapsed/refractory multiple myeloma, even patients that relapsed after B-cell maturation antigen (BCMA)-targeted therapy. Patients with myeloma may have compromised T-cell health unaccounted for by preclinical models. Here, we use Myeloma Drug Sensitivity Testing (My-DST) <i>ex vivo</i> measurement of anti-multiple cytotoxicity the trispecific CD38/CD28xCD3 TCE SAR442257 through...